Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2022

Open Access 01-12-2022 | Metastasis | Case report

Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report

Authors: Yojiro Ishikawa, Motohisa Suzuki, Hisashi Yamaguchi, Ichiro Seto, Masanori Machida, Yoshiaki Takagawa, Keiichi Jingu, Yasuyuki Kikuchi, Masao Murakami

Published in: Journal of Medical Case Reports | Issue 1/2022

Login to get access

Abstract

Background

Radical esophagectomy for esophageal squamous cell carcinoma has improved survival, but the rate of recurrence is high. Patients of recurrent esophageal squamous cell carcinoma after failure of chemotherapy have a poor prognosis. We herein report the achievement of long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma after failure of chemotherapy.

Case presentation

A 60-year-old Japanese man was diagnosed as having squamous cell carcinoma of the lower thoracic esophagus (cT2N0M0, stage IIA). He underwent two courses of neoadjuvant chemotherapy with cisplatin and 5-fluorouracil, and esophagectomy with three-field lymphadenectomy was performed. Microscopic findings after resection showed two lymph node metastases (ypT2N1M0, stage IIB). Five months after resection, a computed tomography scan revealed a solitary liver metastasis in the S4 area. He underwent three courses of chemotherapy with cisplatin and 5-fluorouracil; however, positron emission tomography revealed two lymph node metastases. Surgeons recommended second-line chemotherapy, but the patient refused chemotherapy and requested proton beam therapy. We performed proton beam therapy without chemotherapy for the liver metastasis and lymph node metastases, with total doses of 79.2 and 60 Gy relative biological effectiveness, respectively, according to the tumor location. An acute side effect of grade 1 dermatitis occurred after proton beam therapy, but there was no acute or late complication of more than grade 2. The patient remains in complete remission 5 years after treatment without surgery or chemotherapy.

Discussion and conclusions

Proton beam therapy exerted a curative effect on oligorecurrent esophageal squamous cell carcinoma. This is the first report on the achievement of long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma.
Literature
1.
go back to reference Bhansali MS, Fujita H, Kakegawa T, Yamana H, Ono T, Hikita S, et al. Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg. 1997;21(3):275–81.CrossRef Bhansali MS, Fujita H, Kakegawa T, Yamana H, Ono T, Hikita S, et al. Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg. 1997;21(3):275–81.CrossRef
2.
go back to reference Hulscher JBF, Van Sandick JW, Tijssen JGP, Obertop H, Van Lanschot JJB. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg. 2000;191(2):143–8.CrossRef Hulscher JBF, Van Sandick JW, Tijssen JGP, Obertop H, Van Lanschot JJB. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg. 2000;191(2):143–8.CrossRef
3.
go back to reference Liu Q, Cai XW, Wu B, Zhu ZF, Chen HQ, Fu XL. Patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma: implications for the clinical target volume design of postoperative radiotherapy. PLoS ONE. 2014;9(5):1–6. Liu Q, Cai XW, Wu B, Zhu ZF, Chen HQ, Fu XL. Patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma: implications for the clinical target volume design of postoperative radiotherapy. PLoS ONE. 2014;9(5):1–6.
4.
go back to reference Hsu PK, Wang BY, Huang CS, Wu YC, Hsu WH. Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection. J Gastrointest Surg. 2011;15(4):558–65.CrossRef Hsu PK, Wang BY, Huang CS, Wu YC, Hsu WH. Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection. J Gastrointest Surg. 2011;15(4):558–65.CrossRef
5.
go back to reference Ku GY. Systemic therapy for esophageal cancer: chemotherapy. Chin Clin Oncol. 2017;6(5):1–10. Ku GY. Systemic therapy for esophageal cancer: chemotherapy. Chin Clin Oncol. 2017;6(5):1–10.
6.
go back to reference Makishima H, Ishikawa H, Terunuma T, Hashimoto T, Yamanashi K, Sekiguchi T, et al. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J Radiat Res. 2014;56(3):568–76.CrossRef Makishima H, Ishikawa H, Terunuma T, Hashimoto T, Yamanashi K, Sekiguchi T, et al. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J Radiat Res. 2014;56(3):568–76.CrossRef
7.
go back to reference Hirano Y, Onozawa M, Hojo H, Motegi A, Zenda S, Hotta K, et al. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol. 2018;13(1):1–9.CrossRef Hirano Y, Onozawa M, Hojo H, Motegi A, Zenda S, Hotta K, et al. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol. 2018;13(1):1–9.CrossRef
8.
go back to reference Williamson JF. Physics contribution. Ini J Radiat Oncol Biol Phys. 1998;41(4):959–70.CrossRef Williamson JF. Physics contribution. Ini J Radiat Oncol Biol Phys. 1998;41(4):959–70.CrossRef
9.
go back to reference Zhang X, le Zhao K, Guerrero TM, Mcguire SE, Yaremko B, Komaki R, et al. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 2008;72(1):278–87.CrossRef Zhang X, le Zhao K, Guerrero TM, Mcguire SE, Yaremko B, Komaki R, et al. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 2008;72(1):278–87.CrossRef
10.
go back to reference Gaitanidis A, Alevizakos M, Tsalikidis C, Tsaroucha A, Simopoulos C, Pitiakoudis M. Refusal of cancer-directed surgery by breast cancer patients: risk factors and survival outcomes. Clin Breast Cancer. 2018;18(4):e469–76.CrossRef Gaitanidis A, Alevizakos M, Tsalikidis C, Tsaroucha A, Simopoulos C, Pitiakoudis M. Refusal of cancer-directed surgery by breast cancer patients: risk factors and survival outcomes. Clin Breast Cancer. 2018;18(4):e469–76.CrossRef
11.
go back to reference Nemoto K, Ariga H, Kakuto Y, Matsushita H, Takeda K, Takahashi C, et al. Radiation therapy for loco-regionally recurrent esophageal cancer after surgery. Radiother Oncol. 2001;61(2):165–8.CrossRef Nemoto K, Ariga H, Kakuto Y, Matsushita H, Takeda K, Takahashi C, et al. Radiation therapy for loco-regionally recurrent esophageal cancer after surgery. Radiother Oncol. 2001;61(2):165–8.CrossRef
12.
go back to reference Muroi H, Nakajima M, Satomura H, Takahashi M, Domeki Y, Murakami M, et al. Effectiveness of proton beam therapy on liver metastases of esophageal cancer: report of a case. Int Surg. 2015;100(1):180–4.CrossRef Muroi H, Nakajima M, Satomura H, Takahashi M, Domeki Y, Murakami M, et al. Effectiveness of proton beam therapy on liver metastases of esophageal cancer: report of a case. Int Surg. 2015;100(1):180–4.CrossRef
13.
go back to reference Ono T, Wada H, Ishikawa H, Tamamura H, Tokumaru S. Proton beam therapy is a safe and effective treatment in elderly patients with esophageal squamous cell carcinoma. Thoracic Cancer. 2020;11(8):2170–7.CrossRef Ono T, Wada H, Ishikawa H, Tamamura H, Tokumaru S. Proton beam therapy is a safe and effective treatment in elderly patients with esophageal squamous cell carcinoma. Thoracic Cancer. 2020;11(8):2170–7.CrossRef
14.
go back to reference Kato K, Tahara M, Hironaka S, Muro K, Takiuchi H, Hamamoto Y, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011;67(6):1265–72.CrossRef Kato K, Tahara M, Hironaka S, Muro K, Takiuchi H, Hamamoto Y, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011;67(6):1265–72.CrossRef
15.
go back to reference Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, et al. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2009;4(8):1017–21. Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, et al. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2009;4(8):1017–21.
16.
go back to reference Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer. 2011;117(7):1409–14.CrossRef Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer. 2011;117(7):1409–14.CrossRef
17.
go back to reference Cho S-H, Chung I-J, Song S-Y, Yang D-H, Byun J-R, Kim Y-K, et al. Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer. J Korean Med Sci. 2005;20(4):618–23.CrossRef Cho S-H, Chung I-J, Song S-Y, Yang D-H, Byun J-R, Kim Y-K, et al. Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer. J Korean Med Sci. 2005;20(4):618–23.CrossRef
18.
go back to reference Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer. 2003;89(4):630–3.CrossRef Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer. 2003;89(4):630–3.CrossRef
19.
go back to reference Bidoli P, Stani SC, De Candis D, Cortinovis D, Parra HS, Bajetta E. Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus. Tumori. 2018;87(5):299–302.CrossRef Bidoli P, Stani SC, De Candis D, Cortinovis D, Parra HS, Bajetta E. Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus. Tumori. 2018;87(5):299–302.CrossRef
20.
go back to reference Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40(2):107–11.CrossRef Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40(2):107–11.CrossRef
21.
go back to reference Jingu K, Matsushita H, Takeda K, Umezawa R, Takahashi C, Sugawara T, et al. Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. BMC Cancer. 2012;12. Jingu K, Matsushita H, Takeda K, Umezawa R, Takahashi C, Sugawara T, et al. Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. BMC Cancer. 2012;12.
22.
go back to reference Depypere L, Lerut T, Moons J, Coosemans W, Decker G, Van Veer H, et al. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road. Dis Esophagus. 2017;30(1):1–8.PubMed Depypere L, Lerut T, Moons J, Coosemans W, Decker G, Van Veer H, et al. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road. Dis Esophagus. 2017;30(1):1–8.PubMed
23.
go back to reference Zhao X, Kang J, Zhao R. Abscopal effect of radiation on lymph node metastasis in esophageal carcinoma: a case report and literature review. Oncol Lett. 2018;16(3):3555–60.PubMedPubMedCentral Zhao X, Kang J, Zhao R. Abscopal effect of radiation on lymph node metastasis in esophageal carcinoma: a case report and literature review. Oncol Lett. 2018;16(3):3555–60.PubMedPubMedCentral
Metadata
Title
Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report
Authors
Yojiro Ishikawa
Motohisa Suzuki
Hisashi Yamaguchi
Ichiro Seto
Masanori Machida
Yoshiaki Takagawa
Keiichi Jingu
Yasuyuki Kikuchi
Masao Murakami
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2022
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-022-03275-0

Other articles of this Issue 1/2022

Journal of Medical Case Reports 1/2022 Go to the issue